ARTICLE | Clinical News
Afinitor everolimus regulatory update
April 18, 2011 7:00 AM UTC
FDA's Oncologic Drugs Advisory Committee (ODAC) voted 10-0 that Novartis' Afinitor everolimus had a favorable benefit-risk profile to treat advanced pancreatic neuroendocrine tumors. The sNDA is under...